摘要
目的 :探讨尿端粒酶和尿血管内皮生长因子 (vascularendothelialgrowthfactor ,VEGF)作为瘤标联合诊断膀胱移行细胞癌 (BTCC)的价值。方法 :4 5例BTCC患者 ,分别以TRAP法检测尿端粒酶 ,以抗体夹心ELISA法检测尿VEGF ,并按前期研究结果取 10 5ng gCr为截断点 ,使诊断特异度为 95 %。联合检测时二者之一为阳性即判阳性。结果 :联合检测的灵敏度为 93 3% ,高于任一单项瘤标的灵敏度(端粒酶为 77 8% ,VEGF为 84 4 % ) ,与尿细胞学检查 (4 4.4 % )比较差异有显著意义 ,χ2 =2 2 86 3,P <0 0 0 5。结论 :把对浅表性、低病理分级BTCC敏感的尿瘤标端粒酶与反映肿瘤浸润和预后的尿瘤标VEGF联合 ,能显著提高诊断的灵敏度 ,防止漏诊。
Objective To evaluate the combined examination of urinary telomerase and vascular endothelial growth factor (VEGF) to detect bladder transitional cell carcinoma.Methods Voided urine samples from 45 cases of BTCC were collected.Telomerase was determined by telomeric repeat amplification protocol(TRAP);VEGF was quantified by enzyme linked immunosorbent assay(ELISA) and its cutoff was 105 ng/gCr which gave a 95% specificity according to the results previous to this study.Either VEGF or telomerase had a positive result,BTCC was diagnosed.Results The sensitivity of combined examination of urinary VEGF and telomerase was 93.3%,it's higher than individual tumor marker (telomerase:77.8%,VEGF:84.4%)respectively;there was a significant difference compared with cytology,χ 2=22.863,P<0.005.Conclusions The combination of urinary telomerase which was more sensitive for detecting low grade and/or superficial bladder cancer and urinary VEGF which was a prognostic marker and reflected invasion of BTCC,seemed to be more effective.Its sensitivity was superior to that of the individual or cytology.
出处
《肿瘤防治杂志》
2003年第11期1167-1169,共3页
China Journal of Cancer Prevention and Treatment
